Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Patients with neovascular Age-related macular degeneration (AMD) and the particular feature
of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for
ranibizumab (Lucentis). The PrONTO study was the first ranibizumab study to enroll such
patients but only treated with ranibizumab until fluid within the layers of the retina was
absent, not until the entire PED was absent. This study hypothesizes that there may be a
difference in benefit between patients treated until just the retinal edema is gone and those
in which the retinal edema and PED are both gone.